机构名称：
¥ 1.0
umbrella study to investigate tolerability, Pk, and antitumor activity of ARV-471 (PF- 07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study a (ARV-471 in combination with Abemaciclib) PI: Rachel Layman SM: Lamiae Sahnoune（lsahnoune@mdanderson.org，713-792-7173）g。 2023-0130：Tactive-U：介入的安全性和功效阶段1b/2，开放标签
临床管理 - 肺炎 - web-algorithm.pdf
主要关键词
相关文件推荐
